19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with
relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of
19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find
this dose, they can test it in future participants to see if it is effective in treating
their relapsed/refractory B-cell cell cancers. This study will also look at whether
19(T2)28z1xx CAR T cells work against participants' cancer.